Enlivex Cuts Costs, Focuses on Allocetra Phase 2b Trial for Knee OA
Enlivex cuts costs, slashes staff, and focuses all R&D on its FDA‑designated Phase 2b Allocetra trial for older adults with knee osteoarthritis—aiming for mid‑2027 results.
2 minutes to read